Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02120469

Title field or adapter rule

{'original_value': 'Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.069189+00:00

Published At

2022-04-25T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2022-04-25

Source Retrieved At

2026-10-31T22:18:22.973355+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor-negative", "Stage IV Breast Cancer", "Triple-negative Breast Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT02120469"

protocolSection.identificationModule.officialTitle

"Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2022-04-25", "type": "ACTUAL"}

Study condition terms

• Estrogen Receptor Negative (protocolSection.conditionsModule.conditions)
• HER2/Neu Negative (protocolSection.conditionsModule.conditions)
• Progesterone Receptor-negative (protocolSection.conditionsModule.conditions)
• Stage IV Breast Cancer (protocolSection.conditionsModule.conditions)
• Triple-negative Breast Carcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Treatment (everolimus, eribulin mesylate)'], 'description': 'Given PO', 'name': 'everolimus', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (everolimus, eribulin mesylate)'], 'description': 'Given IV', 'name': 'eribulin mesylate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (everolimus, eribulin mesylate)'], 'description': 'Correlative studies', 'name': 'pharmacological study', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (everolimus, eribulin mesylate)'], 'description': 'Optional correlative studies', 'name': 'laboratory biomarker analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• everolimus (protocolSection.armsInterventionsModule.interventions[].name)
• eribulin mesylate (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.